Rapid response to fluoxetine in women with premenstrual dysphoric disorder

Depression and Anxiety

Volumn 29, Issue 6, 2012, Pages 531-540

  Steinberg, Emma M ^a   Cardoso, Graca M P ^b   Martinez, Pedro E ^a   Rubinow, David R ^c   Schmidt, Peter J ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NOVA MEDICAL SCHOOL   (Portugal)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

fluoxetine; premenstrual dysphoric disorder; selective serotonin reuptake inhibitors; treatment response

Indexed keywords

FLUOXETINE;

ANXIETY; ARTICLE; CLINICAL ARTICLE; DRUG RESPONSE; FEMALE; HUMAN; IRRITABILITY; LUTEAL PHASE; MENSTRUAL CYCLE; OUTCOME ASSESSMENT; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; THERAPY EFFECT; VISUAL ANALOG SCALE;

EID: 85027948466     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.21959     Document Type: Article

References (33)

1. Kornstein SG, Pearlstein TB, Fayyad R, et al. Low-dose sertraline in the treatment of moderate-to-severe premenstrual syndrome: efficacy of 3 dosing strategies. J Clin Psychiatry 2006; 67: 1624-1632. (Pubitemid 44787448)
2. Landen M, Erlandsson H, Bengtsson F, et al. Short onset of action of a serotonin reuptake inhibitor when used to reduce premenstrual irritability. Neuropsychopharmacology 2009; 34: 585-592.
3. Su T-P, Schmidt PJ, Danaceau M, et al. Effect of menstrual cycle phase on neuroendocrine and behavioral responses to the serotonin agonist m-chlorophenylpiperazine in women with premenstrual syndrome and controls. J Clin Endocrinol Metab 1997; 82: 1220-1228. (Pubitemid 27166668)
4. Bancroft J,. The premenstrual syndrome-a reappraisal of the concept and the evidence. Psychol Med 1993;(Suppl 24): 1-47.
5. Rubinow DR, Roy-Byrne PP, Hoban MC, et al. Prospective assessment of menstrually related mood disorders. Am J Psychiatry 1984; 141: 684-686. (Pubitemid 14139461)
6. Smith MJ, Schmidt PJ, Rubinow DR,. Operationalizing DSM-IV criteria for PMDD: selecting symptomatic and asymptomatic cycles for research. J Psychiatr Res 2003; 37: 75-83. (Pubitemid 35449773)
7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994
8. Steiner M, Haskett RF, Carroll BJ,. Premenstrual tension syndrome: the development of research diagnostic criteria and new rating scales. Acta Psychiatr Scand 1980; 62: 177-190. (Pubitemid 10045563)
9. Endicott J, Harrison W,. Daily Rating of Severity of Problems Form. New York, NY: New York State Psychiatric Institute, Department of Research Assessment and Training, 1990.
10. Haskett RF, Abplanalp JM,. Premenstrual tension syndrome: diagnostic criteria and selection of research subjects. Psychiatry Res 1983; 9: 125-138.
11. Brzezinski AA, Wurtman JJ, Wurtman RJ, et al. d-Fenfluramine suppresses the increased calorie and carbohydrate intakes and improves the mood of women with premenstrual depression. Obstet Gynecol 1990; 76: 296-301. (Pubitemid 20227476)
12. Miner C, Brown E, McCray S, et al. Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial. Clin Ther 2002; 24: 417-433. (Pubitemid 34275863)
13. Schmidt PJ, Nieman LK, Grover GN, et al. Lack of effect of induced menses on symptoms in women with premenstrual syndrome. N Engl J Med 1991; 324: 1174-1179.
14. Pinna G, Costa E, Guidotti A,. Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake. Psychopharmacology 2006; 186: 362-372. (Pubitemid 43800838)
15. Lee J-J, Hahm E-T, Lee C-H, et al. Serotonergic modulation of GABAergic and glutamatergic synaptic transmission in mechanically isolated rat medial preoptic area neurons. Neuropsychopharmacology 2008; 33: 340-352. (Pubitemid 350243339)
16. A receptor binding and benzodiazepine-resistant anxiety. J Neurosci 2000; 20: 2758-2765. (Pubitemid 30220299)
17. Heine PA, Taylor JA, Iwamoto GA, et al. Increased adipose tissue in male and female estrogen receptor-α knockout mice. Proc Natl Acad Sci USA 2000; 97: 12729-12734.
18. Robichaud M, Debonnel G,. Modulation of the firing activity of female dorsal raphe nucleus serotonergic neurons by neuroactive steroids. J Endocrinol 2004; 182: 11-21. (Pubitemid 39076898)
19. Dimmock PW, Wyatt KM, Jones PW, et al. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet 2000; 356: 1131-1136.
20. Yonkers KA, Halbreich U, Freeman E, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment: a randomized controlled trial. J Am Med Assoc 1997; 278: 983-988. (Pubitemid 27430194)
21. Brown J, O'Brien PMS, Marjoribanks J, et al. Selective serotonin reuptake inhibitors for premenstrual syndrome (review). Cochrane Libr 2009; 2: CD001396.
22. Shah NR, Jones JB, Aperi J, et al. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis. Obstet Gynecol 2008; 111: 1175-1182. (Pubitemid 351620354)
23. Steiner M, Steinberg S, Stewart D, et al. Fluoxetine in the treatment of premenstrual syndrome. N Engl J Med 1995; 332: 1529-1534.
24. Sundblad S, Modigh K, Andersch B, et al. Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial. Acta Psychiatr Scand 1992; 85: 39-47.
25. Halbreich U, Smoller JW,. Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J Clin Psychiatry 1997; 58: 399-402. (Pubitemid 27438692)
26. Sundblad C, Hedberg MA, Eriksson E,. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial. Neuropsychopharmacology 1993; 9: 133-145. (Pubitemid 23275839)
27. Freeman EW, Rickels K, Sondheimer SJ, et al. Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder. Am J Psychiatry 2004; 161: 343-351. (Pubitemid 38419285)
28. Eriksson E, Ekman A, Sinclair S, et al. Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder. J Clin Psychopharmacol 2008; 28: 195-202. (Pubitemid 351417125)
29. Landen M, Nissbrandt H, Allgulander C, et al. Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder. Neuropsychopharmacology 2007; 32: 153-161. (Pubitemid 44967793)
30. Wikander K, Sundblad C, Andersch B, et al. Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J Clin Psychopharmacol 1998; 18: 390-398. (Pubitemid 28462629)
31. Jermain DM, Preece CK, Sykes RL, et al. Luteal phase sertraline treatment for premenstrual dysphoric disorder: results of a double-blind, placebo-controlled, crossover study. Arch Fam Med 1999; 8: 328-332.
32. Yonkers KA, Holthausen GA, Poschman K, et al. Symptom-onset treatment for women with premenstrual dysphoric disorder. J Clin Psychopharmacol 2006; 26: 198-202. (Pubitemid 43740347)
33. Nichols JH, Charlson JR, Lawson GM,. Automated HPLC assay of fluoxetine and norfluoxetine in serum. Clin Chem 1994; 40: 1312-1316. (Pubitemid 24205950)